Clinical Trials - September 11, 2017
Celgene and AstraZeneca report update on clinical trial programme
MedImmune, AstraZeneca’s global biologics R&D arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION programme. The trials are testing Imfinzi (durvalumab), an anti-PD-L1 agent, in combination with immunomodulatory agents, with or […]
Collaboration - April 29, 2015
AZ, Celgene Tackle Blood Cancer
AstraZeneca has entered into a $450 million agreement with Celgene that will permit the U.S.-based drug firm to develop MEDI4736, AstraZeneca’s immunotherapy treatment for blood cancer. The agreement sent Celgene’s stock surging. AstraZeneca officials say the deal is a way to get the drug to market faster, according to Reuters. Blood cancer treatments eventually will […]